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Theactivation ofT lymphocytes appears to be amultiple step procedure initiated
by direct cell-cellcontact betweenTlymphocytesand antigen-bearing ortarget cells
(1). Initial T cell-target cell interaction progresses to T cell activation if the target
expresses an antigen orsome otherligand able todeliver an activation signal through
the antigen-specific TCRCD3 complex (2-4). The initial interaction, aswell as the
triggering process, seems to involve several receptor-ligand pairs in addition to the
TCR-target cell interaction.
Cell surface proteins thought to play a role in T lymphocyte-target cell adhesion
include CD8 (5, 6), CD4(7, 8), LFA-1 (9, 10), and CD2 (10, 11). Recent experiments
have begun todelineatethe target cell ligands forthese receptor molecules. A variety
ofexperimental approaches have indicated that LFA-3 and ICAM-1 are target cell
ligands for CD2 and LFA-1, respectively (12-14). CD4 and CD8 were initially be-
lieved to be phenotypic markers for functional T cell subsets (15-17). However, the
existence ofCD8+ Th specific for MHC class I products and of CD4+ cytotoxic
Tcells specific forMHC class II products ledto thehypothesis thatphenotype corre-
lates with the class ofMHC protein recognized. This suggested that CD4 and CD8
might be receptors forclassII and class I MHC molecules, respectively (18-21). The
abilityto blockT cell functions withmAbs directed against CD4 andCD8 is consis-
tent with these mAbs disrupting areceptor-ligand interaction (22, 23). There is also
evidence, however, that these mAbs may be capable of delivering an "off signal" to
the cells (24, 25).
Evidence that the interaction ofCD4 and class II molecules augments T cell acti-
vation hasbeen providedbyinfectingamurine Tcellhybridomathat produces IL-2
in response to human HLA-DR antigens with aretroviral vector containing human
CD4 cDNA (26). Similar resultswere reported with anothermurine Tcellhybridoma,
specific for H-2 class I molecules and transfected with a cDNA clone for human
CD4 (27). A direct interaction between HLA-DR and CD4 was demonstrated by
showing that monkey CV1 cells, transiently expressing high levels ofCD4, bind to
human B cells bearing MHC class II molecules (28).
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ADHESION MEDIATED BY CD8 AND CLASS I INTERACTION
Gene transfer techniques have also offered a complementary approach to eluci-
date the role of the CD8 molecule in T cell activation. Reconstitution of MHC class
I specificity by transfer of the TCR and Lyt-2 genes to recipient T cells demon-
strates that the expression of the CD8 molecule is necessary for these T cells to in-
teract with their targets (29, 30). The functional involvement of CD8 in T cell trig-
gering was also demonstrated by showing that a murine T cell hybridoma specific
for HLA class 11 antigens transfected with a cDNA clone for human CD8 specifically
interacts with class I+ cells (31). These data support the idea that class I MHC mol-
ecules encode a ligand for CD8.
In a previous report we describe the preparation of lipid-sealed spherical nylon
vesicles with the size and density of an intact cell (13). These vesicles, termed artificial
target cells (ATCs),' were reconstituted with purified cell surface glycoprotein LFA-
3. ATC bearing LFA-3 formed conjugates with CD2+CD8- T cells, whereas ATCs
prepared without surface proteins or with purified HLA class I protein failed to
interact with the CD2 + cells. The specificity of the interaction between LFA-3 ATCs
and CD2* cells was demonstrated by the ability of mAb against CD2 or LFA-3 to
block the vesicle cell adhesion (13) . In the present study, we have used ATCs bearing
purified CD8 and ATCs bearing HLA class I proteins to demonstrate a direct receptor-
ligand interaction between CD8 and MHC class I molecules capable of mediating
adhesion. We also used ATCs and purified proteins to determine if membrane-
associated CD2 will bind to membrane-associated LFA-3. These data provide direct
evidence that an interaction between CD2 and LFA-3 or between CD8 and HLA
class I molecules can mediate cell-cell adhesion.
Materials and Methods
Cell Lines and mAbs.
￿
The cell linesused wereJY, an EBVtransformed B cell line expressing
high amounts of HLA and LFA-3 ; Jurkat, a T cell line expressing CD2; 16 .T8-15, a CD8'
hybridoma derived from the infection ofthe murine T cell hybridoma By155.16 with a defec-
tive retrovirus containing a cDNA clone for human CD8, as described (31) . The mAbs used
were anti-CD8, OKT8 (IgG2a) (32); antiframework HLA, W6/32 (IgG2a) (33); anti-HLA-
A2 MA2.1 (IgGI), PA2 .1 (IgGI) (34, 35); anti-HLA-B7 MEl (IgGI) and MB40.2 (IgGI) (36,
37) (all purchased from American Type Collection, Rockville, MD); anti-LFA-3, TS2/9 (38);
and anti-CD2, TS2/18, (38). W6/32, TS2/18, and OKT8 were purified from ascites on an
Affi-gel protein A column (Biorad Laboratories, Richmond, CA). TS2/9 was purified by
preparative ion-exchange high-pressure liquid chromatography (13). Anti-A2 and anti-B7
were used as ascites. In adhesion assays all mAbs were used at a final concentration of 10 4g/ml.
Affinity Purification of the Different Cell Surface Molecules.
￿
Purified mAbs were coupled to
Sepharose 4B-CnBr (Pharmacia Fine Chemicals, Piscataway, NJ), according to the instruc-
tions of the manufacturer. HLA class I molecules and LFA-3 were purified from JY cells
by using a Sepharose 4B-W6/32 and a Sepharose 4BTS2/9 column, respectively (13). The
CD2 molecule was purified as described (39), by passing the cell lysate fromJurkat cells over
a Sepharose 4BTS2/18 column. CD8 was isolated from the murine T cell hybridoma 16.T8-15,
which expresses a high density of human CD8 on the cell surface as a result ofinfection with
a defective retrovirus containing a cDNA for human CD8 (31). Optimal elution conditions
for CD8 purification from 16.T8-15 cell lysates were determined as follows. Sepharose 4B-
OKT8 beads were loaded with 10" 16.T8-15 cellular equivalents in 10 mM tris, pH 8, 0.15 M
NaCl, 0.5% Triton X-100. After washing with the same buffer, the beads were divided in
three aliquots, and eluted under different conditions: pH 3, pH 11, or 3.5 M KSCN. Eluted
Abbreviation used in this haper: ATC, artificial target cells.ROSENSTEIN ET AL.
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samples (100-150 gl) were analyzed by SDS-PAGE (10%) under reducing conditions, using
the buffer system of Laemmli (40). The gels were stained with Coomassie blue and silver
stain. The best approach, with respect to yield, purity, and serological activity ofCD8 were
as follows. The lysate-loaded column was washed with 10 vol of 10 mM tris, 0.15 M NaCl,
0.5% Triton X-100, pH 8. The column was then washed with 5 vol of 10 mM tris, 0.5%
Triton X-100, 0.5 M NaCl, pH 8, followed by 5 vol of 10 mM tris 0.5% Triton X-100, 0.5
M NaCl, pH 9. Elution of CD8 was performed with 50 mM Gly, 0.15 M NaCl, DOC 0.1%,
pH 11.5. Fractions (2 ml) were collected in tubes containing enough 1OX PBS, pH 5 to bring
the pH of eluted samples to a pH of 8-8.5. The CD8-enriched fractions, identified by im-
munodot (data not shown), were further purified over a Sepharose 4B-wheat germ agglu-
tinin column; the CD8 protein was eluted with 5% n-acetyl-o-glucosamine in PBS-0.2% octyl-
0-glucoside (41).
SDS-PAGE analysis of the CD8' fractions demonstrated a major band at Mr 34,000 cor-
responding to monomeric CD8 along with a minor contaminant at M, 46,000 (Fig. 1). The
SDS-PAGE of dot blot-identified CD2' fractions revealed a broad band at M, 54,000 with
small amounts of lower molecular weight proteins (Fig. 1). The band at M, 54,000 and the
smaller bands are recognized by anti-CD2 mAb on a Western blot (data not shown).
Preparation ofA7Ls ExpressingMembrane Proteins.
￿
The preparation ofthese vesicles has been
described in detail elsewhere (13). Briefly, ATCs are spherical vesicles consisting of a porous
nylon matrix surrounding an aqueous compartment containing trapped polymers (protein
and Ficoll) that provide colloidal osmotic pressure to keep the vesicles spherical. The resulting
spherical ATCs are similar in size and density to intact cells and can be centrifuged and viewed
under a microscope. A lipid membrane was constructed by covalent attachment of phos-
phatidylethanolamine to the surface ofthe nylon vesicles. This covalently attached lipidserves
as a template for the formation of the lipid membrane added subsequently by detergent dial-
ysis. After extensive washing with PBS, ATCs bounded by a lipid membrane were recon-
stituted with purified proteins as follows. The affinity-purified protein (6 ug HLA, 10 ug CD8,
10 jig LFA-3, or 11 ug CD2) was mixed with PBS containing 10'lipid-sealed ATCs, diluting
the detergent to 1 mM final concentration. The mixture was dialyzed against three changes
of PBS (1,000 vol each) over a 72-h period to remove the detergent. The ATCs, harvested
from the dialysis tubing, were washed three times with PBS by centrifugation at 300 g to
remove any protein not associated with the vesicles. ATCs were stored in PBS 0.1% BSA,
0.02% azide, and washed twice with PBS before use. Once associated with the ATC mem-
brane, the reconstituted proteins were functionally stable after repeated washing or storage
at 4°C for several months as evidenced by the uniform fluorescence staining pattern visible
by fluorescence microscopy and flow cytometry (Fig. 2).
Flow Cytometry.
￿
Surface expression of membrane proteins on intact cells and ATCs was
analyzed with a cell flow cytometer (Epics V, Coulter Electronics, Inc., Hialeah, FL). Cells
or vesicles (105) were incubated in V-bottomed 96-well plates with 50 ul of the indicated mAb
plus 50 ug of human IgG (Sigma Chemical Co., St. Louis, MO) for 30 min at 4°C. After
two washes with cold PBS containing 2 % FCS, 50 ul ofa 1 :30 dilution of fluorescein-conjugated
F(ab')2 goat anti-mouse IgG + IgM (Tago, Burlingame, CA) was added to the cells for an
additional 30 min at 4°C. Cells or ATCs were washed twice and fixed with 1 % paraformalde-
hyde in PBS before flow cytometry.
Adhesion Assays.
￿
Two different kinds of adhesion assays were done. ATC-cell and ATC-
ATC . To discriminate intact cells from ATCs in ATC-cell adhesion assays, tumor cells were
fluorescein labeled by a 10-min incubation with fluorescein diacetate (10 wg/ml, Molecular
Probes, Eugene, OR) followed by three washes with PBS. When adhesion between two different
populations of ATCs was measured, one ATC group was labeled with fluorescein-modified
phosphatidylethanolamine (10 ug/ml, Avand Polar Lipids, Inc., Birmingham, AL) for 15 min
at 4°C, followed by three washes with cold PBS.
In a typical adhesion assay, ATCs reconstituted with CD8, HLA, LEA-3, CD2, or without
added protein were incubated at different ratios with tumor cells or other ATCs. Samples,
in 30 ~1 of 10% FCS RPMI, were centrifuged for 2 min at 40 g, followed by 2-3-h incuba-
tion at 4°C in a 0.5-ml microcentrifuge tube. To the appropriate samples, mAbs were added
at the beginning ofthe experiment. At the end ofthe incubation period, samples were gently152
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resuspended five times with a pipette tip having an internal diameter of 0.5 mm. To quanti-
tate the percent of conjugates, a small aliquot of sample (7 wl) was placed on a glass slide,
and a 12-mm coverslip was placed over the sample and held in place with fingernail polish.
Observations were made with a light microscope using a fluorescent lamp to locate fluorescein-
labeled cells or ATCs and with phase contrast to determine the location of nonfluorescent
ATCs. A conjugate was defined as a fluorescent ATC tightly associated with at least two
nonfluorescent ATCs or a fluorescent cell associated with two or more ATCs . Samples were
analyzed in duplicate, and three or more counts of at least 100 fluorescent cells or ATCs were
done for each sample and scored as conjugates or nonconjugates . Results are expressed as
the mean value t SEM of the six counts made for each group. The percent of conjugates
was calculated as the totalnumber of conjugates divided by the total number ofcellsor ATCs
observed. For ATC-cell conjugates, background was 3-4%; for ATC-ATC conjugates,
nonspecific binding was -10% in the CD8/HLA studies and N3-5% in the CD2/LFA-3 ex-
periments.
Results
Conjugate Formation between Cells and CD8- or HLAATCs.
￿
ATCs were reconstituted
with affinity-purified HLA class I antigens isolated fromJY cells, an EBVtransformed
B cell line expressing a high density of MHC-encoded molecules. CD8 was purified
from 16.T8-15 cells, a CD8+ hybridoma derived from the infection of the T cell hy-
bridoma By155.16 with a defective retrovirus containing a cDNA clone for CD8 (31)
(Fig. 1). Flow cytometry ofimmunofluorescently labeled vesicles indicated that ATCs
expressed protein levels that were similar to or greater than the intact cells from
which they were purified, except in the case of CD8-ATC/16.T8-15 cells (Fig. 2).
CD8- or HLA-ATCs and fluorescein-labeled JY (HLA+) or 16.T8-15 (CD8+)
cells were mixed at a ratio of 1 :4, centrifuged at 40 g for 2 min, and incubated for
2 h at 4°C. The percentage of cells bound to ATCs was determined by fluorescence
and phases contrast microscopy by counting duplicate samples of at least 100 cells
for each group. ATCs reconstituted with CD8 were able to form fivefold more con-
jugates (22 ± 1%) with JY cells, expressing HLA class I proteins, than did ATCs
lacking surface proteins (4 ± 1%) (Fig. 3) . Similarly, ATCs reconstituted with HLA
class I molecules formed sevenfold more conjugates (29 ± 3%) with the CD8+
16.T8-15 cells than did ATCs lacking surface protein (4 t 1%) (Fig. 3). Conjugate
formation between CD8-ATCs and JY (HLA+) cells as well as between HLA-ATCs
and CD8 + 16T8-15 cells was specifically inhibited by anti-HLA (11 t 2%) or anti-
CD8 mAbs (6 ± 0.5%) (Fig. 3). Neither anti-CD2 nor anti-LFA-3 mAbs inhibited
conjugate formation. The CD8 - (Lyt-2-,3- ) parental murine hybridoma line,
By155 .16, did not form specific conjugates with HLA-ATCs (4 ± 2%) (data not shown
in Fig. 3), the percent of conjugates was comparable (4 ± 1%) with that obtained
with 16.T8-15 cells and ATCs lacking surface proteins.
Conjugate Formation between MHC Class I and CD8ATCs.
￿
Conjugate formation be-
tween ATCs reconstituted with either CD8 or HLA was also evaluated. One popula-
tion of ATCs was labeled with fluorescein-modified phosphatidylethanolamine as
described in Materials and Methods, and conjugate formation was then scored as
the number of conjugates formed between fluorescent and nonfluorescent ATCs .
When CD8-ATCs were mixed with HLA-ATCs, at a 1 :2 ratio, four times more
conjugates were formed (42 t 8%), as compared with the binding between CD8
or HLA-ATCs and ATCs lacking surface protein (10 ± 3%) or LFA-3-ATCs (10 ±
2%) (Fig. 4). Blocking by specific mAbs supported the conclusionthat HLA specificallyROSENSTEIN ET AL .
FIGURE 1 .
￿
SDS-PAGE analysis ofaffinity-purifiedCD8 andCD2under
reducing conditions . Lane 1, No sample (background of an empty lane) ;
lane 2, CD8 (2 ug); lane 3, no sample ; lane 4, CD2 (1 ug) (silver stain,
10% acrylamide gel) .
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FIGURE 2 .
￿
Flow cytometric analysis of surface molecules on intact cells andATCs . (a) Jurkat
cells ; (b)CD2-ATCs ; (c)JY cells; (d)LFA-3-ATCs ; (e)JY cells, (f) HLA-ATCs; (q) 16.T8-15 cells,
(h) CD8-ATCs . Samples were incubated with 50 pl of culture supernatant containing 50 gg human
IgG and -2.5 gg of the following mAbs . a and b were stained with anti-CD2 mAb (TS2/18);
c and dwere stained with anti-LFA-3 mAb (TS2/9); e andfwere stained with anti-HLA mAb
(W6/32) ; and gand h were stained with anti-CD8 mAb (OKT8) . The left curve represents the
background stainingwith fluorescein-conjugated goat anti-mouse IgG + IgM only . All samples
pairs (ATC-cell) were processed the same day.
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FIGURE 3 . Quantitation of
CD8/HLA-mediated conjugates
in a cell/ATC adhesion assay.
Fluorescein-labeledJY (HLA* )
or 16.Tß-15 (CD8') cells were
incubated with CD8-ATCs,
HLA-ATCs, or controlATCs at
a 4 :1 cells/ATC ratio for 2 h at
4°C . Results are expressed as
the percent binding ofJY or
16.T8-15 cells to CD8-ATCs or
HLA-ATCs, respectively . As in-
dicated, the experiments were
carried out in the absence or
presence ofmAb (anti-class I,
poolofMA2.1 + PA2.1 + MEl
+ MB40 .2 ; anti-CD8,OKT8 ;
anti-CD2, TS2/18 ; and anti-
LFA-3, TS 2/9) . Data represent
mean f SEM ATC-cell con-
jugates (n = 6) .
interacts with theCD8 molecule, i .e ., anti-HLA and anti-CD8 mAbs blocked con-
jugate formation between CD8-ATCs and HLA-ATCs to background levels while
mAb to LFA-3 failed to inhibit conjugates (Fig . 4) .
Conjugate Formation between CD2- and LFA-3-ATCs.
￿
For comparison, and to ex-
tend our previous work, we carried out parallel experiments to determine if the in-
teractionbetween purifiedCD2 and LFA-3 would mediateATC-ATC conjugate for-
mation . When incubating CD2-ATCs with LFA-3-ATCs at a 1 :1 ratio, we found
nine times more conjugates (43 ± 2%) as compared with thebindingofCD2-ATCs
to HLA-ATCs (4 ± 3%) or ATCs lacking surface protein (5 t 0.5%) . Anti-CD2
mAb reduced conjugate formation to background (4 t 3%), whereas mAbs against
HLA classI antigens did not blockthese CD2-LFA-3 conjugates (36 ± 5%)(Fig. 4) .
When the ratio of CD2 to LFA-3-ATC was increased (from 1 :1 to 1 :4), most of
theconjugateshad theconfiguration ofarosette made ofthree or more LFA-3-ATCs
per CD2-ATC (Fig . 5, C and D) . In comparison, increasing the ratio of CD8-ATC
FIGURE 4 . Purified CD8 interacts
with purifiedHLAclass I protein and
mediates ATC-ATC adhesion . CD8-
ATCs were mixed with HLA-ATCs at
a 1:2 ratio, and vesicle-vesicle con-
jugates scored in the absence or pres-
ence of mAb (see Fig . 3) . Conjugate
formation between CD2-ATCs and
LEA-3-ATCs (at a 1 :1 ratio) was as-
sessed . Results are expressed as the per-
cent of CD8-ATCs binding to HLA-
ATCs or the percent of LFA-3-ATCs
binding to CD2-ATCs . Data represent
mean values ± SEM (n = 6) .ROSENSTEIN ET AL .
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FIGURE 5.
￿
Conjugates between different populations ofATCs . CD8-ATCs and CD2-ATCs fluores-
cently labeled with fluorescein-modified phosphatidylethanolamine were incubated with HLA-
ATCs andLFA-3-ATCs, respectively, under the experimental conditions described in Fig. 4 (not
1 :1 but 1 :4 [see text]) . CD8-HLA conjugate under phase contrast (A) ; fluorescence microscopy
(B). CD2/LFA-3 conjugates under phase contrast (C); fluorescence microscopy (D) .
to HLA-ATC to 1 :4 did notresult inachange in the conjugates size, most consisting
of two to three HLA-ATC per CD8-ATC (Fig . 5, A and B) .
Discussion
Nonspecificconjugate formation between effectorTcells and target cells precedes
the recognition of the specific antigen by the TCR. Previous studies relied largely
upon mAb inhibition to identify the surface proteins involved in cell-cell adhesion
(5-14) . The abilityof severalT cell-reactive mAbs to inhibitT cell-target cell binding
suggests that several different receptors, each interacting with its specific ligand, may
be required to establish cell-cell adhesion . However, it has also been suggested that
mAbs may block function by inhibiting T lymphocyte signal transduction rather
than by directly inhibitinga receptor-ligand interaction (24, 25) . Therefore, the in-
hibitory effects of mAbs on intact cells must be interpreted with caution .156
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The use ofartificial target cells is one approach to identify receptor-ligand pairs
involved in cell-cell adhesion. ATCshave an outer lipidmembrane, are the size and
density of intact cells, and can be reconstituted with purified proteins. The ability
to incorporate a high surface densityofreceptor or ligand onto theATC membrane
enables multivalent interactions tooccur, making itpossible todetect protein-protein
interactionsthat individually may have a low affinity. The adhesion ofthesevesicles,
mediated by purified proteins, provides a direct and unambiguous method to iden-
tify receptor-ligand pairs ableto mediate cell adhesion. This direct approacheliminates
the possibility that other molecules on the cell surface might be interacting with the
ligand or, that adhesion is mediated by other receptor-ligand pairs. We report here
that purified CD8 molecules or HLA class I antigens incorporated into artificial
membranes can mediate adhesion to either HLA+ or CD8+ cells, respectively. Fur-
thermore, we show that artificial target cells, reconstitutedwith either purified CD8
or class I molecules, will form conjugates when incubated together.
Incell-ATC adhesion experiments thenumber ofconjugates scored betweenCD8-
ATCs andJY cells was fivefold greaterthan background binding, and sevenfoldmore
conjugates were formed between the mouse T cell hybridoma expressing human
CD8, 16.T8-15 cells, and HLA-reconstituted ATCs as compared with background.
When CD8-ATCs were mixed with HLA-ATCs, there were four times more con-
jugates formed as compared with background binding. Failure of all the protein-
reconstituted ATCs to form conjugates may depend uponmultiple factors, including
the density ofreceptors and ligands, the association and dissociation constants, the
avidity of the interaction, the mobility ofthe various components, and the confor-
mation ofthe proteins. The conjugates between CD8-ATCs and HLA-ATCs were
found to be specifically inhibited by mAbs to CD8 or HLA class I molecules. The
specificity ofthis interaction was further confirmed by the inability of an irrelevant
mAb (anti-LFA-3) to block conjugate formation and by the absence of conjugate
formation betweenATCs exhibitingLFA-3 molecules and CD8-ATCs orHLA-ATCs.
Taken together, these results demonstrate that HLA class I molecules are a ligand
for the CD8 receptor.
Experimental data regarding CD8 suggest that this molecule may play several
roles on the surface of T lymphocytes. CD8, in conjunction with other accessory
molecules, such as CD2 and LFA-1, may facilitate the interaction ofthe TCR with
its specific antigen throughthe adhesion ofthe T lymphocyte to the target cell. The
associationofCD8 with the MHC class I moleculemight notonlymediate adhesion
butcould also increase the localconcentration ofclass I molecules and favor a proper
orientation of the MHC-Ag peptide complex required for triggering through the
TCR. In addition toits involvement withconjugateformation, CD8 has been reported
to modulate the activation signal of the TCR-CD3 complex. Anti-CD3-mediated
Tcell activation has been found to be enhanced by the presence ofanti-CD8 mAb
(42) whereasonthe other hand, lectin-mediated T celllysis can be inhibited by anti-
CD8 mAbs (24).
Although some ofthe moleculesinvolved in cell-cell adhesion havebeen identified,
little is knownregardingthemolecularmechanismby which adhesion and de-adhesion
is regulated. In the case ofthe CD8-HLA receptor-ligand pair, one possible mecha-
nism is suggested by a recent report indicating that the CD8 molecule is noncova-
lently associated with class I molecules on the surface ofactivated TlymphocytesROSENSTEIN ET AL.
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(43). Assuming that CD8 interacts with one MHC molecule at a time, the ability
of the CD8-HLA class I complex to interact with the target cell HLA would depend
upon the relative density of the class I molecules on the target cell . Once formed,
the T cell-target cell conjugate might be reversed by re-establishing the intracellular
association of CD8 and HLA on the T cell surface. For CD8 and other receptors
involved with adhesion, it is possible that intracellular vs. intercellular binding of
receptor-ligand pairs regulate adhesion and de-adhesion .
T cell activation can be divided into several steps: antigen-nonspecific adhesion,
antigen recognition, and T cell triggering. CD8, as other accessory molecules (LFAI,
CD2, and CD4), may provide more than one function: increasing T cell-target cell
binding and positively and/or negatively regulating T cell activation. T cell trig-
gering may be controlled by regulating only a few of the multiple interactions in-
volved in the different phases of T cell activation. In this report we demonstrate that
the association between CD8 and class I MHC was sufficient to mediate conjugate
formation between cells or cell-sized vesicles.
Summary
Adhesion of T lymphocytes is an essential step for antigen recognition and lym-
phocyte activation. mAbs to T cell surface proteins have been used to define the
receptor-ligand proteins that appear to be involved in adhesion. Since most assays
measure the effects of mAbs on T lymphocyte function, it is not known whether
mAb-mediated blocking is due to a disruption ofreceptor-ligand interactions or results
in inhibition of some aspect of receptor-mediated triggering. It has been suggested
that the CD8 molecule augments T cell avidity for the target cells by binding to
determinants on target cell MHC class I molecules. In the present report, we demon-
strated that purified CD8 molecules incorporated into large lipid vesicles (artificial
target cells) mediate the adhesion of these vesicles to cells expressing HLA proteins,
while vesicles expressing purified HLA class I antigens bind to CD8+ T cells. Fur-
thermore, vesicles bearing CD8 will form conjugates with vesicles expressing HLA
class I proteins. These conjugates were found to be specifically inhibited by mAbs
to CD8 or HLA class I molecules. We also demonstrate that C132-reconstituted vesicles
can form conjugates with vesicles bearing LFA-3 . These experiments provide direct
evidence for an interaction of the CD8 molecule with class I MHC proteins as well
as between CD2 proteins and LFA-3 proteins, thus supporting the hypothesis that
these molecules can mediate cell-cell adhesion .
Note added in proof: Transfection of the human CD8a gene into murine T cell hybridomas
does not rescue expression of murine CD80 (Ratnofsky et a1., unpublished data) .
Receivedfor publication 29 April 1988 and in revisedfarm 20July 1988.
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